ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer.
Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R.
Nat Rev Clin Oncol. 2015 Oct;12(10):573-83. doi: 10.1038/nrclinonc.2015.117. Epub 2015 Jun 30.
IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis.
Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, Verstegen NJM, Ciampricotti M, Hawinkels LJAC, Jonkers J, de Visser KE.
Nature. 2015 Jun 18;522(7556):345-348. doi: 10.1038/nature14282. Epub 2015 Mar 30.
Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role.
Lloyd MR, Wander SA, Hamilton E, Razavi P, Bardia A.
Ther Adv Med Oncol. 2022 Jul 30;14:17588359221113694. doi: 10.1177/17588359221113694. eCollection 2022.
Pigeons (Columba livia) as Trainable Observers of Pathology and Radiology Breast Cancer Images.
Levenson RM, Krupinski EA, Navarro VM, Wasserman EA.
PLoS One. 2015 Nov 18;10(11):e0141357. doi: 10.1371/journal.pone.0141357. eCollection 2015.
Mechanism of Bazhen decoction in the treatment of colorectal cancer based on network pharmacology, molecular docking, and experimental validation.
Lu S, Sun X, Zhou Z, Tang H, Xiao R, Lv Q, Wang B, Qu J, Yu J, Sun F, Deng Z, Tian Y, Li C, Yang Z, Yang P, Rao B.
Front Immunol. 2023 Sep 20;14:1235575. doi: 10.3389/fimmu.2023.1235575. eCollection 2023.
Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination.
Huh HD, Sub Y, Oh J, Kim YE, Lee JY, Kim HR, Lee S, Lee H, Pak S, Amos SE, Vahala D, Park JH, Shin JE, Park SY, Kim HS, Roh YH, Lee HW, Guan KL, Choi YS, Jeong J, Choi J, Roe JS, Gee HY, Park HW.
Mol Cancer. 2023 Mar 30;22(1):63. doi: 10.1186/s12943-023-01753-7.
Identification of circulating metabolites linked to the risk of breast cancer: a mendelian randomization study.
Zhu X, Huang H, Zou M, Luo H, Liu T, Zhu S, Ye B.
Front Pharmacol. 2024 Sep 11;15:1442723. doi: 10.3389/fphar.2024.1442723. eCollection 2024.
Conducive target range of breast cancer: Hypoxic tumor microenvironment.
Cheng W, Xiao X, Liao Y, Cao Q, Wang C, Li X, Jia Y.
Front Oncol. 2022 Sep 26;12:978276. doi: 10.3389/fonc.2022.978276. eCollection 2022.
Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review.
Serrano García L, Jávega B, Llombart Cussac A, Gión M, Pérez-García JM, Cortés J, Fernández-Murga ML.
Front Immunol. 2024 Dec 13;15:1513421. doi: 10.3389/fimmu.2024.1513421. eCollection 2024.
The role of hypoxia-inducible factor-1 alpha in multidrug-resistant breast cancer.
Yong L, Tang S, Yu H, Zhang H, Zhang Y, Wan Y, Cai F.
Front Oncol. 2022 Aug 8;12:964934. doi: 10.3389/fonc.2022.964934. eCollection 2022.
